Overview
Aragon Pharmaceuticals is a privately held, small-molecule drug discovery company focused on developing breakthrough medicines for the treatment of hormonally-driven cancers. These cancers eventually become resistant to existing 1st generation antihormonal therapies, and follow-up treatments are largely ineffective or toxic. The company’s lead compound, ARN-509, is a novel antiandrogen currently undergoing a Phase I/II clinical trial in patients with progressive, advanced castration-resistant prostate cancer. In addition to ARN-509, Aragon is advancing several compounds designed to both block and destroy hormone receptors that drive tumor growth. These agents should be effective in all stages of endocrine driven tumors including prostate and breast cancer and have potential in treating endometrial and ovarian cancer. The agents offer an opportunity to be superior to 1st generation anti-hormonal agents and therefore provide the opportunity for Aragon to expand its pipeline to early stage disease.
Explore the Site
News
- April 4, 2013
Aragon Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer - February 11, 2013
Aragon Announces Key Strategic Hire: Paul Cleveland Joins as EVP of Corporate Strategy and Chief Financial Officer - January 4, 2013
Aragon Wins Key Legal Ruling Against Medivation - October 4, 2012
Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers